Skip to main content
. 2021 May 26;41(11):2944–2956. doi: 10.1177/0271678X211020587

Figure 4.

Figure 4.

Integrated perfusion, permeability, and plasma protein biomarkers of cavernous angioma with symptomatic hemorrhage (CASH) within a year prior to imaging. (a) Canonical score of the integrated perfusion and plasma biomarker was higher (p < 0.001) in CASH (median [interquartile range (IQR)]=0.61 [0.20–0.91]) than non-CASH patients (0.005 [0.001–0.01]). (b) The integrated biomarker (100%, sensitivity, 85% specificity, area under the curve (AUC) [95% confidence interval (CI)]=95% [89–100%], p = 0.0001) distinguished CASH patients (N = 7) from non-CASH patients (N = 46) than perfusion (86% sensitivity, 89% specificity, AUC [95% CI]=89% [73–100%], p = 0.001) or plasma individually (100% sensitivity, 52% specificity, AUC [95% CI]=78% [63–92%], p = 0.018). (c) Similarly, the canonical score of the integrated permeability and plasma biomarker was higher (p < 0.001) in CASH (median [IQR]=0.60 [0.35–0.70]) than non-CASH patients (0.004 [0.001–0.02]). (d) The integrated biomarker (100% sensitivity, 80% specificity, AUC [95% CI]=95% [88–100%], p = 0.0002) distinguished CASH (N = 7) from non-CASH patients (N = 49) better than permeability (71% sensitivity, 94% specificity, AUC [95% CI]=88% [75–100%], p = 0.001) or plasma alone (100% sensitivity, 53% specificity, AUC [95% CI]=79% [65–93%], p = 0.015). *** p < 0.001. AU: arbitrary unit.